MX2023013492A - Moduladores de los receptores acoplados a proteinas g. - Google Patents
Moduladores de los receptores acoplados a proteinas g.Info
- Publication number
- MX2023013492A MX2023013492A MX2023013492A MX2023013492A MX2023013492A MX 2023013492 A MX2023013492 A MX 2023013492A MX 2023013492 A MX2023013492 A MX 2023013492A MX 2023013492 A MX2023013492 A MX 2023013492A MX 2023013492 A MX2023013492 A MX 2023013492A
- Authority
- MX
- Mexico
- Prior art keywords
- chemical entities
- glp
- gipr
- disorder
- disease
- Prior art date
Links
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 title 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 title 1
- 102100039997 Gastric inhibitory polypeptide receptor Human genes 0.000 abstract 4
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 4
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 abstract 4
- 150000005829 chemical entities Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 101000886866 Homo sapiens Gastric inhibitory polypeptide receptor Proteins 0.000 abstract 3
- 230000008484 agonism Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000011664 signaling Effects 0.000 abstract 2
- 230000008485 antagonism Effects 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Holo Graphy (AREA)
- Gyroscopes (AREA)
- Amplifiers (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163188342P | 2021-05-13 | 2021-05-13 | |
| PCT/US2022/029305 WO2022241287A2 (en) | 2021-05-13 | 2022-05-13 | Modulators of g-protein coupled receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013492A true MX2023013492A (es) | 2024-02-29 |
Family
ID=82019613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013492A MX2023013492A (es) | 2021-05-13 | 2022-05-13 | Moduladores de los receptores acoplados a proteinas g. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US12281149B2 (https=) |
| EP (1) | EP4337682A2 (https=) |
| JP (1) | JP2024517942A (https=) |
| KR (1) | KR20240007251A (https=) |
| CN (1) | CN117980325A (https=) |
| AU (1) | AU2022272251A1 (https=) |
| BR (1) | BR112023023559A2 (https=) |
| CA (1) | CA3220005A1 (https=) |
| CL (1) | CL2023003369A1 (https=) |
| CO (1) | CO2023015805A2 (https=) |
| CR (1) | CR20230530A (https=) |
| DO (1) | DOP2023000247A (https=) |
| EC (1) | ECSP23093673A (https=) |
| GE (1) | GEAP202416419A (https=) |
| IL (1) | IL308392A (https=) |
| JO (1) | JOP20230291A1 (https=) |
| MX (1) | MX2023013492A (https=) |
| PE (1) | PE20240890A1 (https=) |
| TW (1) | TW202313666A (https=) |
| WO (1) | WO2022241287A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3204051A1 (en) | 2021-01-20 | 2022-07-28 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| US12281149B2 (en) * | 2021-05-13 | 2025-04-22 | Carmot Therapeutics, Inc. | Modulators of G-protein coupled receptors |
| JP7642830B2 (ja) | 2021-09-15 | 2025-03-10 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
| JP2025530024A (ja) * | 2023-01-18 | 2025-09-10 | シャンハイ ミンウェイ バイオテクノロジー カンパニー，リミテッド | 三重活性を有する融合タンパク質およびその応用 |
| TW202500575A (zh) * | 2023-05-21 | 2025-01-01 | 美商卡默療法股份有限公司 | 具有或不具有體重相關合併症之過重或肥胖成人之治療 |
| CN120981457A (zh) | 2023-09-14 | 2025-11-18 | 歌礼制药(中国)有限公司 | Glp-1r激动剂及其治疗方法 |
| TW202521534A (zh) | 2023-11-24 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
| US20260116848A1 (en) | 2024-07-31 | 2026-04-30 | Carmot Therapeutics Inc. | Synthesis of an Intermediate and Its Use for the Preparation of GLP-1R/GIPR Agonists |
| WO2026027650A1 (en) | 2024-08-02 | 2026-02-05 | F. Hoffmann-La Roche Ag | Process for the preparation of 2-(3-cyano-5-fluorophenyl)-2-methyl-propionic acid |
| WO2026073030A1 (en) | 2024-09-27 | 2026-04-02 | Carmot Therapeutics Inc. | Combination therapy of peptide tyrosine-tyrosine (pyy) analogues and glp-1r agonists |
| CN119930843B (zh) * | 2025-01-22 | 2025-12-30 | 北京康乐卫士生物技术股份有限公司 | 具有glp和gip双重活性的融合蛋白及其应用 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1072649C (zh) | 1995-09-13 | 2001-10-10 | 武田药品工业株式会社 | 苯并氧杂吖庚因化合物,其生产方法和用途 |
| US6432947B1 (en) | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
| JP2002506792A (ja) | 1998-02-27 | 2002-03-05 | ノボ ノルディスク アクティーゼルスカブ | Ｎ末端修飾ｇｌｐ−１誘導体 |
| CZ295044B6 (cs) | 1998-12-07 | 2005-05-18 | Societe De Conseils De Recherches Et D'application | Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující |
| CN1364167A (zh) | 1999-02-26 | 2002-08-14 | 阿瑞那制药公司 | G蛋白偶联受体6的小分子调节剂 |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| WO2001017568A2 (en) | 1999-09-07 | 2001-03-15 | Conjuchem, Inc. | Bioconjugation in vivo to pulmonary or blood components |
| CA2416384A1 (en) | 2000-07-17 | 2003-01-16 | Takeda Chemical Industries, Ltd. | Sulfone derivatives, their production and use |
| AU2003278600A1 (en) | 2002-11-01 | 2004-05-25 | Takeda Pharmaceutical Company Limited | Agent for preventing or treating neuropathy |
| CA2505322A1 (en) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | Receptor function regulator |
| US20070004736A1 (en) | 2002-11-22 | 2007-01-04 | Keiji Kubo | Imidazole derivative, process for producing the same, and use |
| WO2004067548A2 (en) | 2003-01-31 | 2004-08-12 | Theratechnologies Inc. | Chemically modified metabolites of regulatory peptides and methods of producing and using same |
| EP1630152A4 (en) | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | CONDENSED CYCLIC COMPOUND |
| BR122019021416A2 (https=) | 2003-09-19 | 2019-12-21 | ||
| EP1669352A4 (en) | 2003-09-30 | 2008-12-17 | Takeda Pharmaceutical | THIAZOLINE DERIVATIVE AND ITS USE |
| GB0325644D0 (en) | 2003-11-04 | 2003-12-10 | Avidex Ltd | Immuno ihibitory pyrazolone compounds |
| EP1695961A4 (en) | 2003-12-17 | 2007-10-24 | Takeda Pharmaceutical | UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE |
| AU2004309271A1 (en) | 2003-12-25 | 2005-07-14 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl)propanoic acid derivatives |
| WO2005063725A1 (ja) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | フェニルプロパン酸誘導体 |
| JP4875978B2 (ja) | 2004-03-15 | 2012-02-15 | 武田薬品工業株式会社 | アミノフェニルプロパン酸誘導体 |
| US7517910B2 (en) | 2004-03-30 | 2009-04-14 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| US20060275288A1 (en) | 2005-01-20 | 2006-12-07 | Grihalde Nelson D | GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof |
| US8957070B2 (en) | 2005-04-20 | 2015-02-17 | Takeda Pharmaceutical Company Limited | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity |
| CA2607566A1 (en) | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use |
| EP1916234B1 (en) | 2005-07-29 | 2014-11-12 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
| US20090054435A1 (en) | 2005-07-29 | 2009-02-26 | Hiroshi Imoto | Phenoxyalkanoic Acid Compound |
| TW200740435A (en) | 2005-08-10 | 2007-11-01 | Takeda Pharmaceuticals Co | Therapeutic agent for diabetes |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| RS53230B (sr) | 2006-06-27 | 2014-08-29 | Takeda Pharmaceutical Company Limited | Kondenzovana ciklična jedinjenja kao modulatori gpr40 receptora |
| WO2008021560A2 (en) | 2006-08-17 | 2008-02-21 | Amylin Pharmaceuticals, Inc. | Dpp-iv resistant gip hybrid polypeptides with selectable properties |
| US8492405B2 (en) | 2006-10-18 | 2013-07-23 | Takeda Pharmaceutical Company Limited | Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity |
| RU2454415C9 (ru) | 2006-10-19 | 2013-02-27 | Такеда Фармасьютикал Компани Лимитед | Производное индола |
| EP2128138A1 (en) | 2007-01-29 | 2009-12-02 | Takeda Pharmaceutical Company Limited | Pyrazole compound |
| JP2010517935A (ja) | 2007-02-09 | 2010-05-27 | 武田薬品工業株式会社 | Ｐｐａｒ−ガンマのパーシャルアゴニストとしての縮合環化合物 |
| JPWO2008136428A1 (ja) | 2007-04-27 | 2010-07-29 | 武田薬品工業株式会社 | 含窒素５員複素環化合物 |
| WO2008156757A1 (en) | 2007-06-19 | 2008-12-24 | Takeda Pharmaceutical Company Limited | Indazole compounds for activating glucokinase |
| HUE032284T2 (en) | 2008-03-18 | 2017-09-28 | Novo Nordisk As | Protease-stabilized, acylated insulin analogues |
| CN102105159B (zh) | 2008-06-17 | 2015-07-08 | 印第安纳大学研究及科技有限公司 | 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症 |
| TW201006821A (en) | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
| US20120148586A1 (en) | 2009-08-27 | 2012-06-14 | Joyce Ching Tsu Chou | Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders |
| US8426414B2 (en) | 2009-10-09 | 2013-04-23 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
| KR20120123443A (ko) | 2010-01-27 | 2012-11-08 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트 |
| WO2011143365A1 (en) | 2010-05-13 | 2011-11-17 | Amgen Inc. | Nitrogen heterocyclic compounds useful as pde10 inhibitors |
| US20120021979A1 (en) | 2010-06-24 | 2012-01-26 | Vanderbilt University | GLP-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction |
| WO2012088379A2 (en) | 2010-12-22 | 2012-06-28 | Marcadia Biotech, Inc. | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides |
| DK2710031T3 (en) | 2011-05-18 | 2018-01-02 | Mederis Diabetes Llc | IMPROVED PEPTID MEDICINALS FOR INSULIN RESISTANCE |
| US9453062B2 (en) | 2011-06-10 | 2016-09-27 | Beijing Hanmi Pharmaceutical Co., Ltd. | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof |
| WO2013148579A1 (en) | 2012-03-29 | 2013-10-03 | Cebix Inc. | Pegylated c-peptide |
| AU2013341711A1 (en) | 2012-11-12 | 2015-05-21 | Redwood Bioscience, Inc. | Compounds and methods for producing a conjugate |
| WO2014088432A1 (en) | 2012-12-06 | 2014-06-12 | Callaghan Innovation Research Limited | Conjugate compounds |
| US9766239B2 (en) | 2013-03-13 | 2017-09-19 | Arizona Board Of Regents On Behalf Of Arizona State University | Synbodies for detection of human norovirus |
| EP3604271A1 (en) | 2013-06-28 | 2020-02-05 | Auckland Uniservices Limited | Peptides for amino acid and peptide conjugates and conjugation process |
| WO2015031268A1 (en) | 2013-08-26 | 2015-03-05 | Arizona Board Of Regents On Behalf Of Arizona State University | High affinity synbodies for influenza |
| GB2528436A (en) | 2014-07-15 | 2016-01-27 | Lancaster Univ Business Entpr Ltd | Treatment of neurological diseases |
| CN108271356A (zh) * | 2014-09-24 | 2018-07-10 | 印第安纳大学研究及科技有限公司 | 肠降血糖素-胰岛素缀合物 |
| EP3218414A1 (en) | 2014-11-14 | 2017-09-20 | Angiochem Inc. | Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin |
| TWI582109B (zh) | 2015-01-09 | 2017-05-11 | 美國禮來大藥廠 | Ｇｉｐ及ｇｌｐ－１共促效劑化合物 |
| WO2016131893A1 (en) | 2015-02-18 | 2016-08-25 | Medimmune Limited | Incretin fusion polypeptides |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| GB2551945B (en) | 2015-12-18 | 2021-09-08 | Heptares Therapeutics Ltd | Novel GLP-1 receptor agonist peptides |
| GB201620611D0 (en) | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
| MX2020009950A (es) * | 2018-03-23 | 2021-04-28 | Carmot Therapeutics Inc | Moduladores de receptores acoplados a proteina g. |
| TWI799680B (zh) | 2019-01-29 | 2023-04-21 | 美商美國禮來大藥廠 | 製備gip/glp1雙重促效劑之方法 |
| CN110684082B (zh) | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
| TW202216746A (zh) | 2020-06-22 | 2022-05-01 | 印度商太陽製藥工業有限公司 | 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑 |
| EP4230640A4 (en) | 2020-10-16 | 2024-11-20 | Hanmi Pharm. Co., Ltd. | GLP-1/GIP DOUBLE AGONIST, LONG-ACTING CONJUGATE THEREOF AND PHARMACEUTICAL COMPOSITION THEREOF |
| PE20231309A1 (es) | 2020-10-17 | 2023-08-24 | Sun Pharmaceutical Ind Ltd | Agonistas duales glp-1/gip |
| CN114617956B (zh) | 2020-12-10 | 2023-10-03 | 江苏中新医药有限公司 | 一种高效降糖的蛋白质药物 |
| KR20220092442A (ko) | 2020-12-24 | 2022-07-01 | 한미약품 주식회사 | 신규한 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중활성체 및 이의 용도 |
| US12281149B2 (en) * | 2021-05-13 | 2025-04-22 | Carmot Therapeutics, Inc. | Modulators of G-protein coupled receptors |
| WO2023028466A1 (en) | 2021-08-23 | 2023-03-02 | Eli Lilly And Company | Compounds and methods for liquid phase synthesis |
| US20250223331A1 (en) | 2021-09-02 | 2025-07-10 | Sunshine Lake Pharma Co., Ltd. | Glp-1/gip dual-targeted polypeptide and fusion protein and applications thereof |
| WO2023089594A1 (en) | 2021-11-22 | 2023-05-25 | Sun Pharmaceutical Industries Limited | Process for the preparation of tirzepatide or pharmaceutically acceptable salt thereof |
-
2022
- 2022-05-13 US US17/744,540 patent/US12281149B2/en active Active
- 2022-05-13 EP EP22729907.0A patent/EP4337682A2/en active Pending
- 2022-05-13 CA CA3220005A patent/CA3220005A1/en active Pending
- 2022-05-13 GE GEAP202416419A patent/GEAP202416419A/en unknown
- 2022-05-13 PE PE2023003051A patent/PE20240890A1/es unknown
- 2022-05-13 MX MX2023013492A patent/MX2023013492A/es unknown
- 2022-05-13 CR CR20230530A patent/CR20230530A/es unknown
- 2022-05-13 WO PCT/US2022/029305 patent/WO2022241287A2/en not_active Ceased
- 2022-05-13 JP JP2023569936A patent/JP2024517942A/ja active Pending
- 2022-05-13 IL IL308392A patent/IL308392A/en unknown
- 2022-05-13 KR KR1020237042878A patent/KR20240007251A/ko active Pending
- 2022-05-13 AU AU2022272251A patent/AU2022272251A1/en active Pending
- 2022-05-13 BR BR112023023559A patent/BR112023023559A2/pt unknown
- 2022-05-13 CN CN202280048710.4A patent/CN117980325A/zh active Pending
- 2022-05-13 TW TW111118138A patent/TW202313666A/zh unknown
-
2023
- 2023-11-09 DO DO2023000247A patent/DOP2023000247A/es unknown
- 2023-11-10 CL CL2023003369A patent/CL2023003369A1/es unknown
- 2023-11-13 JO JOJO/P/2023/0291A patent/JOP20230291A1/ar unknown
- 2023-11-21 CO CONC2023/0015805A patent/CO2023015805A2/es unknown
- 2023-12-13 EC ECSENADI202393673A patent/ECSP23093673A/es unknown
-
2024
- 2024-07-18 US US18/777,223 patent/US20240383960A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12281149B2 (en) | 2025-04-22 |
| WO2022241287A2 (en) | 2022-11-17 |
| CL2023003369A1 (es) | 2024-05-17 |
| US20230151074A1 (en) | 2023-05-18 |
| ECSP23093673A (es) | 2024-01-31 |
| CO2023015805A2 (es) | 2023-12-11 |
| JOP20230291A1 (ar) | 2023-11-13 |
| DOP2023000247A (es) | 2024-03-28 |
| EP4337682A2 (en) | 2024-03-20 |
| TW202313666A (zh) | 2023-04-01 |
| CA3220005A1 (en) | 2022-11-17 |
| CN117980325A (zh) | 2024-05-03 |
| IL308392A (en) | 2024-01-01 |
| JP2024517942A (ja) | 2024-04-23 |
| PE20240890A1 (es) | 2024-04-24 |
| WO2022241287A3 (en) | 2022-12-29 |
| AU2022272251A1 (en) | 2023-11-16 |
| GEAP202416419A (en) | 2024-03-25 |
| CR20230530A (es) | 2024-02-19 |
| US20240383960A1 (en) | 2024-11-21 |
| BR112023023559A2 (pt) | 2024-02-06 |
| KR20240007251A (ko) | 2024-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023013492A (es) | Moduladores de los receptores acoplados a proteinas g. | |
| MY205468A (en) | Modulators of g-protein coupled receptors | |
| Hirabayashi et al. | Discovery of PACAP and its receptors in the brain | |
| Isaac | Clonidine in the central nervous system: site and mechanism of hypotensive action | |
| Sherman et al. | Hyaluronate receptors: key players in growth, differentiation, migration and tumor progression | |
| SA521431209B1 (ar) | مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1 | |
| DE602005011617D1 (de) | Hochaffiner ny-eso-t-zellen-rezeptor | |
| PE20221273A1 (es) | Receptores del antigeno quimerico anti-cd79, celulas car-t, y usos de estos | |
| MA27565A1 (fr) | Derives de 4-tetrazolyl-4-phenylpiperidine utilises pour le traitement de la douleur | |
| MA43468B1 (fr) | Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2 | |
| CO6210755A2 (es) | Antagonistas del dr6 y usos de los mismos en le tratamiento de transtornos neurologicos | |
| Díaz-Cabiale et al. | Neurochemical modulation of central cardiovascular control: the integrative role of galanin | |
| On et al. | Evolution of parathyroid hormone receptor family and their ligands in vertebrate | |
| WO2021016571A3 (en) | Methods of treating antibody-mediated disorders with fcrn antagonists | |
| DE1812531A1 (de) | Feuerloeschschaum-Konzentrat | |
| PH12022552562A1 (en) | Qd dosing of gip receptor agonist peptide compounds and uses thereof | |
| Fieber | Neurotransmitters and neuropeptides of invertebrates | |
| MX2025012483A (es) | Moduladores de nk3 y usos de los mismos | |
| Martire et al. | Region-specific inhibition of potassium-evoked [3H] noradrenaline release from rat brain synaptosomes by neuropeptide Y-(13–36). Involvement of NPY receptors of the Y2 type | |
| Burnstock | Expanding field of purinergic signaling | |
| Fried et al. | Galanin-, neuropeptide Y-and enkephalin-like immunoreactivities in catecholamine-storing paraganglia of the fetal guinea pig and newborn pig | |
| Cherksey et al. | Tolbutamide and glyburide differ in effectiveness to displace α-and β-adrenergic radioligands in pancreatic islet cells and membranes | |
| Tomura et al. | Enkephalin induces Ca2+ mobilization in single cells of bradykinin-sensitized differentiated neuroblastoma hybridoma (NG108-15) cells | |
| Maurin et al. | Inhibition by yohimbine of the calcium-dependent evoked release of [3H] GABA in rat and mouse brain slices in vitro | |
| Sabbatini et al. | C-type natriuretic peptide stimulates pancreatic exocrine secretion in the rat: role of vagal afferent and efferent pathways |